Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens

Daniele Armenia, Domenico Di Carlo, G. Maffongelli, Vanni Borghi, Claudia Alteri, Federica Forbici, Ada Bertoli, Caterina Gori, Massimo Giuliani, Emanuele Nicastri, Mauro Zaccarelli, Carmela Pinnetti, Stefania Cicalini, Gianpiero D'Offizi, F. Ceccherini-Silberstein, Cristina Mussini, Andrea Antinori, M. Andreoni, Carlo Federico Perno, Mm Santoro

Research output: Contribution to journalArticle

Abstract

Objectives: We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. Methods: Data from 206 drug-naïve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses. Baseline DRV/r resistance and its evolution at failure were also examined. Results: DRV600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD4 cell count and DRV/PI resistance) compared with DRV800. By 12 months, the probability of achieving VS was 93.2% and 84.3% in drug-naïve and PI-experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS, both in drug-naïve patients [>500 000 HIV-1 RNA copies/mL: median [interquartile range (IQR)] 6.1 (5.1-10.3) months; 100 000-500 000 copies/mL: median (IQR) 4.9 (3.8-6.1) months;

Original languageEnglish
Pages (from-to)21-32
JournalHIV Medicine
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2017

Fingerprint

Ritonavir
HIV-1
Viremia
Pharmaceutical Preparations
CD4 Lymphocyte Count
Survival Analysis
Protease Inhibitors
Darunavir
RNA

Keywords

  • Baseline viraemia
  • Darunavir
  • Darunavir dosage
  • Drug resistance
  • Virological response

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy

Cite this

Armenia, D., Di Carlo, D., Maffongelli, G., Borghi, V., Alteri, C., Forbici, F., ... Santoro, M. (2017). Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. HIV Medicine, 18(1), 21-32. https://doi.org/10.1111/hiv.12388

Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. / Armenia, Daniele; Di Carlo, Domenico; Maffongelli, G.; Borghi, Vanni; Alteri, Claudia; Forbici, Federica; Bertoli, Ada; Gori, Caterina; Giuliani, Massimo; Nicastri, Emanuele; Zaccarelli, Mauro; Pinnetti, Carmela; Cicalini, Stefania; D'Offizi, Gianpiero; Ceccherini-Silberstein, F.; Mussini, Cristina; Antinori, Andrea; Andreoni, M.; Perno, Carlo Federico; Santoro, Mm.

In: HIV Medicine, Vol. 18, No. 1, 01.2017, p. 21-32.

Research output: Contribution to journalArticle

Armenia, D, Di Carlo, D, Maffongelli, G, Borghi, V, Alteri, C, Forbici, F, Bertoli, A, Gori, C, Giuliani, M, Nicastri, E, Zaccarelli, M, Pinnetti, C, Cicalini, S, D'Offizi, G, Ceccherini-Silberstein, F, Mussini, C, Antinori, A, Andreoni, M, Perno, CF & Santoro, M 2017, 'Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens', HIV Medicine, vol. 18, no. 1, pp. 21-32. https://doi.org/10.1111/hiv.12388
Armenia, Daniele ; Di Carlo, Domenico ; Maffongelli, G. ; Borghi, Vanni ; Alteri, Claudia ; Forbici, Federica ; Bertoli, Ada ; Gori, Caterina ; Giuliani, Massimo ; Nicastri, Emanuele ; Zaccarelli, Mauro ; Pinnetti, Carmela ; Cicalini, Stefania ; D'Offizi, Gianpiero ; Ceccherini-Silberstein, F. ; Mussini, Cristina ; Antinori, Andrea ; Andreoni, M. ; Perno, Carlo Federico ; Santoro, Mm. / Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. In: HIV Medicine. 2017 ; Vol. 18, No. 1. pp. 21-32.
@article{dc4e79d2f7ab48c9a462b1564fe852f4,
title = "Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens",
abstract = "Objectives: We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. Methods: Data from 206 drug-na{\"i}ve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses. Baseline DRV/r resistance and its evolution at failure were also examined. Results: DRV600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD4 cell count and DRV/PI resistance) compared with DRV800. By 12 months, the probability of achieving VS was 93.2{\%} and 84.3{\%} in drug-na{\"i}ve and PI-experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS, both in drug-na{\"i}ve patients [>500 000 HIV-1 RNA copies/mL: median [interquartile range (IQR)] 6.1 (5.1-10.3) months; 100 000-500 000 copies/mL: median (IQR) 4.9 (3.8-6.1) months;",
keywords = "Baseline viraemia, Darunavir, Darunavir dosage, Drug resistance, Virological response",
author = "Daniele Armenia and {Di Carlo}, Domenico and G. Maffongelli and Vanni Borghi and Claudia Alteri and Federica Forbici and Ada Bertoli and Caterina Gori and Massimo Giuliani and Emanuele Nicastri and Mauro Zaccarelli and Carmela Pinnetti and Stefania Cicalini and Gianpiero D'Offizi and F. Ceccherini-Silberstein and Cristina Mussini and Andrea Antinori and M. Andreoni and Perno, {Carlo Federico} and Mm Santoro",
year = "2017",
month = "1",
doi = "10.1111/hiv.12388",
language = "English",
volume = "18",
pages = "21--32",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens

AU - Armenia, Daniele

AU - Di Carlo, Domenico

AU - Maffongelli, G.

AU - Borghi, Vanni

AU - Alteri, Claudia

AU - Forbici, Federica

AU - Bertoli, Ada

AU - Gori, Caterina

AU - Giuliani, Massimo

AU - Nicastri, Emanuele

AU - Zaccarelli, Mauro

AU - Pinnetti, Carmela

AU - Cicalini, Stefania

AU - D'Offizi, Gianpiero

AU - Ceccherini-Silberstein, F.

AU - Mussini, Cristina

AU - Antinori, Andrea

AU - Andreoni, M.

AU - Perno, Carlo Federico

AU - Santoro, Mm

PY - 2017/1

Y1 - 2017/1

N2 - Objectives: We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. Methods: Data from 206 drug-naïve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses. Baseline DRV/r resistance and its evolution at failure were also examined. Results: DRV600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD4 cell count and DRV/PI resistance) compared with DRV800. By 12 months, the probability of achieving VS was 93.2% and 84.3% in drug-naïve and PI-experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS, both in drug-naïve patients [>500 000 HIV-1 RNA copies/mL: median [interquartile range (IQR)] 6.1 (5.1-10.3) months; 100 000-500 000 copies/mL: median (IQR) 4.9 (3.8-6.1) months;

AB - Objectives: We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir (DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. Methods: Data from 206 drug-naïve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily (DRV600) or 800/100 mg once daily (DRV800) were examined. The probabilities of virological success (VS) and virological rebound (VR) were evaluated in survival analyses. Baseline DRV/r resistance and its evolution at failure were also examined. Results: DRV600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD4 cell count and DRV/PI resistance) compared with DRV800. By 12 months, the probability of achieving VS was 93.2% and 84.3% in drug-naïve and PI-experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS, both in drug-naïve patients [>500 000 HIV-1 RNA copies/mL: median [interquartile range (IQR)] 6.1 (5.1-10.3) months; 100 000-500 000 copies/mL: median (IQR) 4.9 (3.8-6.1) months;

KW - Baseline viraemia

KW - Darunavir

KW - Darunavir dosage

KW - Drug resistance

KW - Virological response

UR - http://www.scopus.com/inward/record.url?scp=84976889258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976889258&partnerID=8YFLogxK

U2 - 10.1111/hiv.12388

DO - 10.1111/hiv.12388

M3 - Article

C2 - 27353061

VL - 18

SP - 21

EP - 32

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 1

ER -